RANKL Inhibition Blocks Osteolytic Lesions and Reduces Skeletal Tumor Burden in Models of Non–Small-Cell Lung Cancer Bone Metastases

Al Husaini, 2009, Prevention and management of bone metastases in lung cancer: a review, J Thorac Oncol, 4, 251, 10.1097/JTO.0b013e31819518fc Roodman, 2004, Mechanisms of bone metastasis, N Engl J Med, 350, 1655, 10.1056/NEJMra030831 Mundy, 2002, Metastasis to bone: causes, consequences and therapeutic opportunities, Nat Rev Cancer, 2, 584, 10.1038/nrc867 Roodman, 2001, Biology of osteoclast activation in cancer, J Clin Oncol, 19, 3562, 10.1200/JCO.2001.19.15.3562 Boyle, 2003, Osteoclast differentiation and activation, Nature, 423, 337, 10.1038/nature01658 Kong, 1999, OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis, Nature, 397, 315, 10.1038/16852 McGrath, 2011, OPG/RANKL/RANK pathway as a therapeutic target in cancer, J Thorac Oncol, 6, 1468, 10.1097/JTO.0b013e318229421f Bu, 2008, Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases, Int J Cancer, 123, 1034, 10.1002/ijc.23625 Lu, 2009, ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis, Genes Dev, 23, 1882, 10.1101/gad.1824809 Thomas, 1999, Breast cancer cells interact with osteoblasts to support osteoclast formation, Endocrinology, 140, 4451, 10.1210/endo.140.10.7037 Feeley, 2006, Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration, J Bone Miner Res, 21, 1571, 10.1359/jbmr.060706 Morony, 2001, Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis, Cancer Res, 61, 4432 Tannehill-Gregg, 2006, The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice, Clin Exp Metastasis, 23, 19, 10.1007/s10585-006-9008-z Zhang, 2001, Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone, J Clin Invest, 107, 1235, 10.1172/JCI11685 Li, 2011, Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone, Bone, 48, 1354, 10.1016/j.bone.2011.03.687 Henry, 2011, Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma, J Clin Oncol, 29, 1125, 10.1200/JCO.2010.31.3304 Scagliotti, 2012, Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study, J Thorac Oncol, 7, 1823, 10.1097/JTO.0b013e31826aec2b Miller, 2008, RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis, Mol Cancer Ther, 7, 2160, 10.1158/1535-7163.MCT-08-0046 Stocking, 2009, Use of low-molecular-weight heparin to decrease mortality in mice after intracardiac injection of tumor cells, Comp Med, 59, 37 Canon, 2008, Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis, Clin Exp Metastasis, 25, 119, 10.1007/s10585-007-9127-1 Kinsella, 1996, Episomal vectors rapidly and stably produce high-titer recombinant retrovirus, Hum Gene Ther, 7, 1405, 10.1089/hum.1996.7.12-1405 Coleman, 2001, Metastatic bone disease: clinical features, pathophysiology and treatment strategies, Cancer Treat Rev, 27, 165, 10.1053/ctrv.2000.0210 Rosen, 2004, Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial, Cancer, 100, 2613, 10.1002/cncr.20308 Tsuya, 2007, Skeletal metastases in non-small cell lung cancer: a retrospective study, Lung Cancer, 57, 229, 10.1016/j.lungcan.2007.03.013 Dougall, 2012, Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis, Clin Cancer Res, 18, 326, 10.1158/1078-0432.CCR-10-2507 Travis, 2013, New pathologic classification of lung cancer: relevance for clinical practice and clinical trials, J Clin Oncol, 31, 992, 10.1200/JCO.2012.46.9270 Li, 2000, Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro, Endocrinology, 141, 2054, 10.1210/endo.141.6.7518 Oyajobi, 2001, Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy, Cancer Res, 61, 2572 Fizazi, 2011, Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study, Lancet, 377, 813, 10.1016/S0140-6736(10)62344-6 Stopeck, 2010, Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study, J Clin Oncol, 28, 5132, 10.1200/JCO.2010.29.7101 Canon, 2012, RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model, Breast Cancer Res Treat, 135, 771, 10.1007/s10549-012-2222-2 Chen, 2011, RANKL increases migration of human lung cancer cells through intercellular adhesion molecule-1 up-regulation, J Cell Biochem, 112, 933, 10.1002/jcb.23009